FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316085290> ?p ?o ?g. }

• W4316085290 endingPage "e864" @default.
• W4316085290 startingPage "e863" @default.
• W4316085290 abstract "Introduction: Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a serious complication in cirrhotic patients, leading to significant morbidity and mortality. The purpose of this study was to evaluate clinical characteristics and treatment (Tx) response of HRS-AKI patients receiving currently available standard of care (SOC) treatment. Methods: Cerner Real World Data (from 113 U.S. health systems) was used to identify adult HRS-AKI (ICD-10, K76.7) patients hospitalized between 2016 and 2020. Patients with baseline serum creatinine (SCr) >1.5mg/dL treated with midodrine (MID), octreotide (OCT), or norepinephrine (NOR) were included. Tx response was assessed based on baseline SCr and post-Tx SCr readings (Day 14 or Tx discontinuation, whichever came first). Complete response was achieved if post-Tx SCr improved to ≤1.5 mg/dL; partial if decreased by ≥30% but remained >1.5 mg/dL; and no response if decreased by < 30%. Tx response by AKI stage using KDIGO guidelines and several comorbidities during hospitalization were also evaluated, including mechanical ventilation (MV), respiratory failure (RF), and fluid overload. Results: A total of 3,918 patients with HRS-AKI (64.5% male, mean age: 59.4±12.7 years) were identified. Most common precipitant included diuretic treatment (79.2%), paracentesis (55.7%), and gastrointestinal bleeding (29.7%). Majority of patients received MID or OCT (n=2,013, 51.4%) or MID+OCT without NOR (n=1,168, 29.8%) and 982 (25.1%) received NOR, regardless of other vasopressors. During hospitalization, 658 (16.8%) patients received MV, of whom 454 (11.6%) had RF. Additionally, 363 patients had RF without MV. Other common comorbid conditions included fluid overload (20.6%), pleural effusion (14.1%), and abdominal pain (9.6%). Complete response was observed in 683 patients overall (17.4%) and patients with AKI stage 1 or 2 (n=2,302) had a higher rate of complete response (13.0% vs 7.6%) and partial response (11.0% vs 8.0%) than patients with AKI stage 3. Additional patient and clinical characteristics are shown in Table. Conclusion: At least one in six HRS-AKI patients required mechanical ventilation, had RF and/or fluid overload during hospitalization. Current SOC for HRS-AKI was ineffective. The results also suggest an inverse relationship between KDIGO-staged AKI and rate of complete response, indicating a benefit for earlier diagnosis and treatment initiation. Table 1. - Additional Patient and Clinical Characteristics Characteristic N=3,918 Patient Demographics Age, years, mean ± SD 59.4 ± 12.7 Male, n (%) 2,528 (64.5) Ethnicity, n (%) White or Caucasian 3,243 (68.2) Black or African American 325 (6.8) Other 1,036 (21.8) Unknown 151 (3.2) Clinical Characteristics Baseline SCr*, mg/dL, mean ± SD 3.0 ± 1.7 Selected treatments, n (%) Midodrine or Octreotide without norepinephrine 2,013 (51.4) Midodrine and Octreotide without norepinephrine 1,168 (29.8) Norepinephrine (regardless of any other vasopressor) 982 (25.1) Etiology of liver disease*, n (%) Alcoholic cirrhosis/hepatitis 1,779 (45.4) Viral hepatitis 560 (14.3) NASH/NAFLD 1,728 (44.1) Precipitants of HRS-AKI*, n (%) Diuretic treatment 3,104 (79.2) Paracentesis 2,183 (55.7) Gastrointestinal bleeding 1,163 (29.7) Other infections 1,101 (28.1) Spontaneous bacterial peritonitis 690 (17.6) Hepatocellular carcinoma 374 (9.5) Use of mechanical ventilation and rate of respiratory failure, n (%) Mechanical ventilation 658 (16.8) Respiratory failure 454 (11.6) No respiratory failure 204 (5.2) No mechanical ventilation 3,260 (83.2) Respiratory failure 363 (9.3) No respiratory failure 2,897 (73.9) Response type by KDIGO-staged AKI No AKI, n (%) 1,103 (28.2) Complete response, n (% of no AKI) 345 (31.3) Partial response, n (% of no AKI) 146 (13.2) No response, n (% of no AKI) 612 (55.5) Stage 1 or 2 AKI, n (%) 2,302 (58.8) Complete response, n (% of Stage 1 or 2 AKI) 299 (13.0) Partial response, n (% of Stage 1 or 2 AKI) 244 (10.6) No response, n (% of Stage 1 or 2 AKI) 1,759 (76.4) Stage 3 AKI, n (%) 513 (13.1) Complete response, n (% of Stage 3 AKI) 39 (7.6) Partial response, n (% of Stage 3 AKI) 41 (8.0) No response, n (% of Stage 3 AKI) 433 (84.4) Comorbid conditions during hospitalization, n (%) Sepsis 846 (21.6) Respiratory failure 817 (20.9) Fluid overload 807 (20.6) Pleural effusion 553 (14.1) Abdominal pain 354 (9.0) Diarrhea 199 (5.1) Bradycardia 123 (3.1) Dyspnea 89 (2.3) Nausea 54 (1.4) *not mutually exclusive. Abbreviations: AKI, acute kidney injury; HRS, hepatorenal syndrome; KDIGO, Kidney Disease Improving Global Outcomes; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; SCr, serum creatinine; SD, standard deviation." @default.
• W4316085290 created "2023-01-14" @default.
• W4316085290 creator A5008007589 @default.
• W4316085290 creator A5011796369 @default.
• W4316085290 creator A5039742422 @default.
• W4316085290 creator A5046898482 @default.
• W4316085290 creator A5054258885 @default.
• W4316085290 date "2022-10-01" @default.
• W4316085290 modified "2023-10-17" @default.
• W4316085290 title "S1187 Clinical and Economic Burden of Patients With HRS-AKI Treated With Current Standard of Care: Retrospective Analysis of Real World Data" @default.
• W4316085290 doi "https://doi.org/10.14309/01.ajg.0000861388.10338.cb" @default.
• W4316085290 hasPublicationYear "2022" @default.
• W4316085290 type Work @default.
• W4316085290 citedByCount "0" @default.
• W4316085290 crossrefType "journal-article" @default.
• W4316085290 hasAuthorship W4316085290A5008007589 @default.
• W4316085290 hasAuthorship W4316085290A5011796369 @default.
• W4316085290 hasAuthorship W4316085290A5039742422 @default.
• W4316085290 hasAuthorship W4316085290A5046898482 @default.
• W4316085290 hasAuthorship W4316085290A5054258885 @default.
• W4316085290 hasBestOaLocation W43160852901 @default.
• W4316085290 hasConcept C126322002 @default.
• W4316085290 hasConcept C2776258039 @default.
• W4316085290 hasConcept C2776988256 @default.
• W4316085290 hasConcept C2777214474 @default.
• W4316085290 hasConcept C2778715236 @default.
• W4316085290 hasConcept C2780306776 @default.
• W4316085290 hasConcept C2780472472 @default.
• W4316085290 hasConcept C2780496750 @default.
• W4316085290 hasConcept C71924100 @default.
• W4316085290 hasConceptScore W4316085290C126322002 @default.
• W4316085290 hasConceptScore W4316085290C2776258039 @default.
• W4316085290 hasConceptScore W4316085290C2776988256 @default.
• W4316085290 hasConceptScore W4316085290C2777214474 @default.
• W4316085290 hasConceptScore W4316085290C2778715236 @default.
• W4316085290 hasConceptScore W4316085290C2780306776 @default.
• W4316085290 hasConceptScore W4316085290C2780472472 @default.
• W4316085290 hasConceptScore W4316085290C2780496750 @default.
• W4316085290 hasConceptScore W4316085290C71924100 @default.
• W4316085290 hasIssue "10S" @default.
• W4316085290 hasLocation W43160852901 @default.
• W4316085290 hasLocation W43160852902 @default.
• W4316085290 hasOpenAccess W4316085290 @default.
• W4316085290 hasPrimaryLocation W43160852901 @default.
• W4316085290 hasRelatedWork W1808892103 @default.
• W4316085290 hasRelatedWork W2068633232 @default.
• W4316085290 hasRelatedWork W2110280698 @default.
• W4316085290 hasRelatedWork W2481561779 @default.
• W4316085290 hasRelatedWork W2486730564 @default.
• W4316085290 hasRelatedWork W2793725462 @default.
• W4316085290 hasRelatedWork W2886031242 @default.
• W4316085290 hasRelatedWork W2949320652 @default.
• W4316085290 hasRelatedWork W3210594219 @default.
• W4316085290 hasRelatedWork W4245890041 @default.
• W4316085290 hasVolume "117" @default.
• W4316085290 isParatext "false" @default.
• W4316085290 isRetracted "false" @default.
• W4316085290 workType "article" @default.